Post-earnings recap
Reported
Tue, May 1, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Biogen's first quarter results showed a slight miss on EPS, which contributed to a 1.63% decline in stock price. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. Management's comments suggest they are focused on innovation but are aware of the challenges ahead.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.40 | N/A | -2.51% |
Management expressed a cautious view on the current market environment. They highlighted their commitment to research and development despite the EPS miss.
Management acknowledged the challenging market conditions.
They emphasized ongoing efforts to drive innovation in their product pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—